with 10 million which includes the tax rebate your EV is around 9 million for a drug that compared to AGN is far superior in its mode of action and mono therapy. AGN was at a 70 million market cap in the same position right now as NYR. To be honest it’s actually significantly undervalued and 45 cents target price is more realistic which it was trading at before any drug was working
Ann: Quarterly Activities Report and Appendix 4C, page-9
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.023(26.4%) |
Mkt cap ! $17.85M | |||
| Open | High | Low | Value | Volume |
| 8.8¢ | 11.5¢ | 8.8¢ | $249.0K | 2.447M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 167181 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 197198 | 6 |
View Market Depth
| Last trade - 12.56pm 03/10/2024 (20 minute delay) ? |
| NYR (ASX) Chart |